Posts by Sandra Ansanay-Alex
AC BioScience closes a 4th seed-round of CHF 2.5 million
AC BioScience, a Biopôle-based clinical-stage biotech company pioneering the development of novel therapies in immuno-oncology and tumour vascular normalization, announces a fourth Seed Round for CHF 2.5 million. Founded by Andreas Schlaepfer and Professor Christian Auclair, AC BioSciences develops personalized molecular therapies designed to optimize efficiency or bolster the therapeutic benefit for particular groups…
Read MoreAlcon buys Aerial Pharmaceutics for $770 million
Ophthalmic devices and Geneva-based Alcon has reached an agreement to acquire North Carolina-based Aerie Pharmaceuticals for $770 million (743.1 million francs). The transaction will strengthen the former Novartis subsidiary’s position in the fields of glaucoma and dry eye. Alcon will acquire Rocklatan (netarsudil and latanoproste) and Rhopressa (netarsudil), which are approved for the reduction…
Read MoreNovartis to list its subsidiary Sandoz on the stock exchange
Under consideration since 2021, the details of the demerger of Sandoz, the generic drug arm of Swiss pharmaceutical giant Novartis, are becoming clearer. It will not be sold, but listed on the Swiss and US stock exchanges in the second half of 2023. Sandoz will be the number one listed generic player in Europe. …
Read MoreTwiice’s exoskeleton allows paralysed people to walk again
Vaud-based and EPFL spin-off startup TWIICE receives a CHF 100 000 seed loan from FIT Every year, around 250,000 people suffer a spinal cord injury resulting in permanent paraplegia. The primary means of mobility for people with paraplegia is the wheelchair, which exposes users to long-term health problems such as loss of bone density,…
Read MoreAbionic’s test diagnoses sepsis 3 days before the standards methods
Abionic’s test identifies in 5 minutes the earliest signs of sepsis 3 days before the standard of care. The technology just received a European IVDR certification for its in-vitro diagnostics. Abionic SA, a developer of disruptive nanotechnology-based diagnostic solutions, announces that its Pancreatic Stone Protein (PSP) test on the abioSCOPE® has been certified by…
Read MoreObsEva plans job cuts
The ObsEva laboratory is to engage in a vast restructuring process in the face of difficulties encountered with the FDA with its drug in development Linzagolix. Job cuts might be on the agenda. The US Drug Administration (FDA) agreed in November 2021 to review the application for the drug to treat heavy periods associated with…
Read MoreDexter®, the Swiss surgery robot, makes its way to Germany
The Dexter® on-demand robotic surgery system created by the swiss company Distalmotion is now used by the Department for Women’s Health and Gynecology at the University Hospital Tübingen in Germany. Prof. Dr. med. Diethelm Wallwiener, Prof. Dr. med. Sara Brucker, Prof. Dr. med. Bernhard Krämer and their teams used theDexter robot in several surgical…
Read MoreDebiopharm signs an new IDEAL agreement with the University of Geneva
Debiopharms and UNIGE want to fight together against cancer and drug-resistant bacterial infections JULY 25, 2022 Debiopharm, a Swiss biopharmaceutical company based in Lausanne, signed of a new agreement as part of its IDEAL (Innovation Debiopharm Academia Léman) initiative with the University of Geneva (UNIGE). The UNIGE Faculty of Medicine has become a partner of the IDEAL program…
Read MoreUsing proteins as barcodes to fight against counterfeiting
Nanodecoder, an EPFL spin-off, receives CHF 100 000 from FIT The Fondation pour l’Innovation Technologique selection committee announced they have made an Innogrant award of CHF 100 000 to NanoDecoder – an EPFL-based project developing nanopore sensing technologies to fight conterfeiting and perform molecular diagnostics. The startup is working on engineered bio-nanopore providing fast…
Read MoreNestlé Health Science invests EUR 40 million in Enterome
Nestlé Health Science has signed a collaboration agreement with French company Enterome to target food allergies and chronic intestinal diseases Enterome develops new treatments for cancer and autoimmune diseases based on its unique knowledge of the microbiota. With Nestlé Health Science, the french company intends to work on the development of an experimental treatment,…
Read More